Exclusive Interview with David Guest, MHRA ahead of Parallel Trade Conference 2021
SMi Reports: SMi Group is proud to introduce some insightful content from expert speaker of the upcoming Parallel Trade conference, taking place 22nd 23rd March.
- (1888PressRelease) March 17, 2021 - The conference now only one week away will bring together industry experts to discuss the challenges and drivers of the industry, including the EU regulatory landscape and the impact of the FMD (Falsified Medicines Directive).
In the run up to the conference we managed to sit down with David Guest, Manager, Parallel Import Unit, MHRA to discuss his thoughts on how COVID-19 is currently impacting the Parallel Trade industry.
You can download the full interview, as well as other free exclusive content, the latest conference agenda, and list of speakers: www.parallel-trade.com/1888pr8
Here is a snapshot of what was discussed - the full version of the interview is available on the download centre.
The Parallel Trade market has matured greatly over recent years, what key differences have you noticed in the last year regarding significant developments?
The biggest development has been the conclusion of transition period, and the necessary preparations associated with that. So far as Great Britain is concerned, companies have had to put effort into defining the parallel import licenses that they require to continue the parallel distribution trade. Another key change is that parallel exports have effectively stopped which has hit certain companies hard, especially if exporting constituted a major part of their business model.
What kind of impact do you think post-Brexit will have on the field of Parallel Trade following the end of the transition period?
Hopefully, and I can only comment on medicines, there will be little regulatory impact which has been our intention. There is a need for the regulatory groups to update all of the patient information, but this is a change that can take place over time rather than being a cliff edge and the intention is that we will not impact the supply of medicines.
We deliberately designed the process to deal with the end of the parallel distribution to require the minimum input from companies, and so far, we have no indication of major problems.
HIGHLIGHTS FOR 2021:
Engage in a platform discussion inclusive of all different facets of parallel trade in analysing the overall state of the market
Explore the effects and impact of the Falsified Medicines Directive and how to best comply to these practices
Collaborate and share ideas of how a hard Brexit will impact the EU market and affect parallel trade practices
Discover what the industry has learnt from COVID-19 and the impact on export bans
Register for the virtual conference: online access here: www.parallel-trade.com/1888pr8
PLUS POST CONFERENCE INTERACTIVE WORKSHOPS:
The law of parallel trade: past, present and future, hosted by Bruckhaus Freshfields Deringer
Masterclass in EU Distribution: Strategy & Implementation hosted by Alira Health
Parallel Trade Conference 2021
Virtual conference: online access only
22nd 23rd March 2021
Proudly sponsored by UL Global Pharma Alira Health
Contact Information:
For media enquiries, contact Jinna Sidhu on Tel: +44 (0)20 7827 6088 or hsidhu ( @ ) smi-online dot co dot uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the worlds most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam